@article{Vale_C-2024_183945,
title = {Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials},
author = {Vale, C. and Godolphin, P. and Fisher, D. and Horby, P. and Kosiborod, M. and Hochman, J. and Webster, K. and Higgins, J. and Althouse, A. and Berwanger, O. and Furtado, R. and Gasparyan, S. and Haynes, R. and Koch, G. and Landray, M. and Leifer, E. and Marshall, J. and Murthy, S. and Neal, M. and Staplin, N. and Diaz, J. and Sterne, J. and Shankar-Hari, M.},
month = {sep},
year = {2024},
abstract = {Sodium glucose co-transporter-2 inhibitors (SGLT2i) have been proposed as a potential treatment for 3 adults hospitalised with COVID-19, due to their potential anti-inflammatory and endothelial protective 4 effects. To-date published evidence from randomised control trials (RCTs) does not provide evidence 5 of benefit. We aimed to estimate the effect of oral administration of SGLT2i compared with usual care 6 or placebo in adults hospitalised with COVID-19.},
journal = {The Lancet Diabetes & Endocrinology},
publisher = {Elsevier},
url = {https://doi.org/10.1016/S2213-8587(24)00219-5},
}
